Understanding immunogenicity, safety, and protective efficacy of next-generation vaccines for tuberculosis.
Role
Supervisor Ethics
Description
Tuberculosis (TB) is the deadliest infectious diseases worldwide, causing 1.5 million deaths annually. TB is caused by a bacterium, Mycobacterium tuberculosis (Mtb), which is transmitted via aerosols from infectious individuals. The rise of multidrug-resistant TB, highlights the worldwide urgent need for effective vaccines to control this disease. Currently, the only licensed TB vaccine for human use, Bacille Calmette-Guérin (BCG), provides limited protection, particularly in adults. This project focuses on improving next-generation TB vaccines by addressing key safety concerns, providing a foundation to evaluate their safety, immunogenicity and efficacy and laying the groundwork for their potential use in clinical settings.
Date
01 Jun 2025 - 01 Jul 2026
Project Type
N/A
Keywords
tuberculosis;BCG
Funding Body
Far North Queensland Hospital Foundation
Amount
5000
Project Team
Andreas Kupz;Andreas Kupz